Trial · NCT01886313
Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve
NCT01886313, Phase 2, Terminated, Winston Laboratories; results first posted 2017-03-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve. Trials, record NCT01886313. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01886313
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve
- NCT number
- NCT01886313
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 11 participants, actual
- Lead sponsor
- Winston Laboratories
- Conditions
- Postherpetic Neuralgia
- Interventions
- Civamide Nasal Spray, Placebo
- First posted
- 2013-06-25
- Last updated
- 2017-03-01
- Results first posted
- 2017-03-01
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Average Daily Pain Score | 6 weeks | The change in the Average Daily Pain Score (11-point Numeric Rating Scale (NRS)) from the Baseline Period to the Average Daily Pain Score of the last week of the Treatment Period. The minimum score is 0 and the maximum score is 10. A score of 0 indicates no pain while a score of 10 indicates worst possible pain. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Average Daily Pain Score | 6 weeks | 1 patient withdrew early from study | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Average Daily Pain Score | Double Blind Treatment Period Civamide Nasal Spray | Baseline | 6.4 | Standard Deviation 0.84 | units on a scale |
| Average Daily Pain Score | Double Blind Treatment Period Placebo Nasal Spray | Baseline | 5.2 | Standard Deviation 1.02 | units on a scale |
| Average Daily Pain Score | Double Blind Treatment Period Civamide Nasal Spray | Week 6 | 5.3 | Standard Deviation 1.24 | units on a scale |
| Average Daily Pain Score | Double Blind Treatment Period Placebo Nasal Spray | Week 6 | 3.1 | Standard Deviation 2.13 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Double Blind Treatment Period Civamide Nasal Spray | 6 | |
| Overall Study | STARTED | Double Blind Treatment Period Placebo Nasal Spray | 5 | |
| Overall Study | COMPLETED | Double Blind Treatment Period Civamide Nasal Spray | 5 | |
| Overall Study | COMPLETED | Double Blind Treatment Period Placebo Nasal Spray | 4 | |
| Overall Study | NOT COMPLETED | Double Blind Treatment Period Civamide Nasal Spray | 1 | |
| Overall Study | NOT COMPLETED | Double Blind Treatment Period Placebo Nasal Spray | 1 |
Source ClinicalTrials.gov
Adverse events28
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Application Site Burning | General disorders | Double Blind Treatment Period Civamide Nasal Spray | 3 | 6 | 11 |
| other | Application Site Burning | General disorders | Double Blind Treatment Period Placebo Nasal Spray | 1 | 5 | 1 |
| other | Application Site Irritation | General disorders | Double Blind Treatment Period Civamide Nasal Spray | 3 | 6 | 17 |
| other | Application Site Irritation | General disorders | Double Blind Treatment Period Placebo Nasal Spray | 0 | 5 | 0 |
| other | Epistaxis | Respiratory, thoracic and mediastinal disorders | Double Blind Treatment Period Civamide Nasal Spray | 0 | 6 | 0 |
| other | Epistaxis | Respiratory, thoracic and mediastinal disorders | Double Blind Treatment Period Placebo Nasal Spray | 2 | 5 | 3 |
| other | Sneezing | Respiratory, thoracic and mediastinal disorders | Double Blind Treatment Period Civamide Nasal Spray | 1 | 6 | 4 |
| other | Sneezing | Respiratory, thoracic and mediastinal disorders | Double Blind Treatment Period Placebo Nasal Spray | 0 | 5 | 0 |
| other | Throat Irritation | Respiratory, thoracic and mediastinal disorders | Double Blind Treatment Period Civamide Nasal Spray | 1 | 6 | 3 |
| other | Throat Irritation | Respiratory, thoracic and mediastinal disorders | Double Blind Treatment Period Placebo Nasal Spray | 0 | 5 | 0 |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Double Blind Treatment Period Civamide Nasal Spray | ||
| Total, all-cause mortality | Double Blind Treatment Period Placebo Nasal Spray | ||
| Total, other adverse events | Double Blind Treatment Period Civamide Nasal Spray | 6 | 6 |
| Total, other adverse events | Double Blind Treatment Period Placebo Nasal Spray | 3 | 5 |
| Total, serious adverse events | Double Blind Treatment Period Civamide Nasal Spray | 0 | 6 |
| Total, serious adverse events | Double Blind Treatment Period Placebo Nasal Spray | 1 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Double Blind Treatment Period Civamide Nasal Spray vs Double Blind Treatment Period Placebo Nasal Spray: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01886313
GET https://conductscience.org/api/trials/v1/NCT01886313/events?page=2